证券代码：002872 证券简称：ST 天圣 公告编号：2025-057 天圣制药集团股份有限公司 关于收到中国证券监督管理委员会重庆监管局 《行政处罚事先告知书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司（以下简称"公司"）及控股股东、实际控制 人刘群先生于 2025 年 1 月 7 日收到中国证券监督管理委员会（以下简称"中国 证监会"）下发的《立案告知书》（编号：证监立案字 0152025001 号、编号： 证监立案字 0152025002 号）。因涉嫌信息披露违法违规，根据《中华人民共和 国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公 司及控股股东、实际控制人刘群先生进行立案。具体内容详见公司于 2025 年 1 月 9 日披露的《关于公司及控股股东、实际控制人收到中国证券监督管理委员 会立案告知书的公告》。 公司及相关人员于 2025 年 9 月 12 日收到中国证监会重庆监管局出具的 《行政处罚事先告知书》（处罚字（2025）4 号），现将相关内容公告如下： 经查明，天圣制药、刘群等涉嫌违 ...

Group 1 - The stock of ST Tian Sheng (002872) closed at 4.78 yuan on September 11, 2025, down 0.21%, with a turnover rate of 1.21% and a trading volume of 26,000 hands, amounting to a transaction value of 12.34 million yuan [1] - On September 11, the net outflow of main funds was 985,600 yuan, while retail investors saw a net inflow of 447,900 yuan [3] - The controlling shareholder Liu Qun was involved in the misappropriation of company funds, with a total of approximately 125 million yuan being misappropriated and later repaid by Liu Qun by April 8, 2021 [1][3] Group 2 - The Chongqing First Intermediate People's Court made a criminal judgment on December 29, 2023, confirming the misappropriation of funds, and Liu Qun has returned the funds [1] - The Chongqing High People's Court upheld the original judgment on August 8, 2024, rejecting Liu Qun's appeal [1] - Beijing Xinghua Accounting Firm issued a qualified opinion on the company's 2024 financial report due to an ongoing investigation by the CSRC regarding information disclosure violations related to the company and Liu Qun [1]

Core Viewpoint - ST Tian Sheng (002872) has been under other risk warnings since June 5, 2019, due to the alleged misappropriation of company funds by its controlling shareholder Liu Qun, who has been ordered to repay a total of 125,074,926 yuan [1] Group 1: Stock Performance - As of September 10, 2025, ST Tian Sheng closed at 4.79 yuan, up 0.42% from the previous trading day, with a total market capitalization of 1.523 billion yuan [1] - The stock opened at 4.75 yuan, reached a high of 4.81 yuan, and a low of 4.74 yuan, with a trading volume of 839.29 thousand yuan and a turnover rate of 0.82% [1] Group 2: Legal and Financial Developments - Liu Qun was sentenced to repay 91.824926 million yuan for misappropriated funds and 33.25 million yuan for misused funds, totaling 125,074,926 yuan [1] - As of April 8, 2021, all principal and interest of the funds occupied by Liu Qun had been fully repaid [1] - On December 29, 2023, the Chongqing First Intermediate People's Court confirmed the misappropriation and misused funds, and Liu Qun has returned the funds [1] - The Chongqing High People's Court upheld the original ruling on August 8, 2024, dismissing Liu Qun's appeal [1] - Beijing Xinghua Accounting Firm issued a qualified opinion on the company's 2024 financial report due to an ongoing investigation by the CSRC regarding information disclosure violations [1] - The company is cooperating with the investigation while maintaining normal production and operations [1]

相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002872 证券简称：ST 天圣 公告编号：2025-054 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 特别提示： 因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易所 股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司"或 "天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 二、采取的措施及有关工作进展情况 1、公司进一步加强了董事、监事、高级管理人员及广大业务人员对相关法 律、法规、制度的学习和培训，提高规范意识，保障各项规章制度的有效落实。 公司正进一步完善内部控制评价机制，确保及时发现内部控制缺陷，及时加以 改进，保证内部控制的有效性；强化内部审计力度，加强对各业务部门业务开 展情况的审计，梳理内控流程，查找流程风险点，评估和分析风险强度，杜绝 资金占用发生，切实维护公司和股东的权益。 1 一、实行其他风险警示事项及主要原因 控股股东刘群涉嫌侵占公司资金，由于刘群部分涉案财物已扣押、冻结、 查封，预计无 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2025-053 天圣制药集团股份有限公司 天圣制药集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 的第六届董事会第十一次会议、第六届监事会第七次会议及 2025 年 5 月 23 日召 开的 2024 年度股东大会审议通过了《关于为参股公司向银行申请授信提供担保 暨关联交易的议案》。同意公司按持股比例 49%为参股公司重庆医药集团长圣医 药有限公司（以下简称"长圣医药"）向银行申请授信提供累计不超过人民币 16,000 万元的担保，具体担保情况以银行核准后所签订的担保合同为准。同时提 请股东大会授权公司经营层代表公司全权办理与本次担保相关事宜，包括但不限 于协议、合同及其他与担保有关的法律性文件的签订、执行。 长圣医药控股股东重庆医药（集团）股份有限公司将按持股比例 51%为长圣 医药向银行申请授信提供同比例担保。本次担保长圣医药未提供反担保。 具 体 内 容 详 见 公 司 于 2025 年 4 月 29 日 刊 载 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上的《关于为参股公司提供担保暨 ...

Core Points - Tian Sheng Pharmaceutical Group Co., Ltd. (ST Tian Sheng) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1][2] - The company and its controlling shareholders may face civil compensation claims from investors who suffered losses due to alleged securities fraud [1][2] - A lawyer from Shanghai Hanlian Law Firm is collecting claims from affected investors, with specific conditions for eligibility outlined [2][3] Summary by Sections Company Investigation - Tian Sheng Pharmaceutical has been notified of a formal investigation by the CSRC due to suspected information disclosure violations [1] - The investigation could lead to civil liabilities for the company, its controlling shareholders, and related parties if investors' rights are found to be compromised [1] Investor Compensation - Affected investors who purchased Tian Sheng Pharmaceutical's securities before January 9, 2025, and sold or held them afterward may register for compensation claims [2] - The final conditions for claims will depend on the outcomes of the CSRC's administrative penalties and subsequent court rulings [2] Legal Process and Requirements - The progress of civil claims may be influenced by the company's potential delisting or bankruptcy proceedings [3] - Investors wishing to register for claims must provide specific documentation, including a copy of their ID and securities transaction records [3]

Core Insights - ST Tian Sheng reported a narrowing loss in its 2025 interim financial results, with total revenue of 232 million yuan, a year-on-year decrease of 17.49% [1] - The company's net profit attributable to shareholders was -36.71 million yuan, an improvement of 14.84% compared to the previous year [1] Financial Performance - Total revenue for Q2 2025 was 117 million yuan, down 12.57% year-on-year [1] - Q2 net profit attributable to shareholders was -24.30 million yuan, a decline of 7.28% year-on-year [1] - Gross margin increased to 48.9%, up 8.54% year-on-year, while net margin decreased to -15.9%, down 2.72% year-on-year [1] - Total selling, administrative, and financial expenses amounted to 141 million yuan, accounting for 60.73% of revenue, an increase of 15.17% year-on-year [1] - Earnings per share were -0.12 yuan, an increase of 14.9% year-on-year, while operating cash flow per share rose significantly to 0.08 yuan, up 449% year-on-year [1] Historical Context - The company has a historical median ROIC of 1.39%, indicating average investment returns, with the worst year being 2020 at -13.77% [2] - Since its listing, the company has reported six years of losses out of seven annual reports, suggesting a generally poor financial performance [2] Business Model - The company's performance is primarily driven by marketing efforts, necessitating a thorough examination of the underlying factors influencing this drive [2] - Cash flow status is a critical area of focus, with the average operating cash flow over the past three years being only 13.81% of current liabilities [2]

证券代码：002872 证券简称：ST 天圣 公告编号：2025-051 天圣制药集团股份有限公司 关于为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 2、湖北天圣拟向中国工商银行股份有限公司十堰郧阳支行申请授信800万 元，借款期限1年。 （一）担保基本情况 为满足日常经营资金需求，天圣制药集团股份有限公司（以下简称"公司"） 之全资子公司湖北天圣药业有限公司（以下简称"湖北天圣"）、天圣制药集团 重庆药物研究院有限公司（以下简称"天圣研究院"）拟向银行申请授信，湖北 天圣申请授信的额度共计不超过人民币 2,300 万元，天圣研究院申请授信的额度 共计不超过人民币 300 万元，公司为上述全资子公司申请授信提供担保，具体担 保情况如下： 1、湖北天圣拟向湖北郧县农村商业银行股份有限公司营业部申请授信1,000 万元，借款期限2年。 （1）以湖北天圣位于郧阳区茶店镇二道坡村、蔡家岭村天圣路1号20幢自用 厂房作为抵押。 （2）以湖北天圣名下"一种丹皮酚制剂的制备方法、一种降香蒸馏液的制 备方法、一种注射液装量检测装 ...

| | | 占用方与 | 上市公 | | 2025 年半年 | 2025 年半年 | 2025 年半年 | | 占用 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 上市公司 | 司核算 | 年期初占 2025 | 度占用累计 | 度占用资金 | 度偿还累计发 | 年半年度期 2025 | 形成 | 占用性 | | | | 的关联关 | 的会计 | 用资金余额 | 发生金额（不 | 的利息(如 | 生金额 | 末占用资金余额 | 原因 | 质 | | | | 系 | 科目 | | 含利息） | 有) | | | | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | ...

天圣制药集团股份有限公司 2025 年半年度财务报告 天圣制药集团股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 天圣制药集团股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：天圣制药集团股份有限公司 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 284,933,275.21 | 270,419,234.88 | | 结算备付金 | 0.00 | 0.00 | | 拆出资金 | 0.00 | 0.00 | | 交易性金融资产 | 0.00 | 0.00 | | 衍生金融资产 | 0.00 | 0.00 | | 应收票据 | 12,818,298.64 | 30,305,965.70 | | 应收账款 | 87,178,271.99 | 120,099,455.35 | | 应收款项融资 | 6,442,160.76 | 7,601,037.37 | | 预付款 ...